Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sucrets Complete

This article was originally published in The Tan Sheet

Executive Summary

Sucrets line extension Sucrets Complete is the first reformulation of the 75-year old brand in at least 10 years, according to Insight Pharmaceuticals President & CEO Jeffrey Nugent. The Blue Bell, Penn.-based firm announced the launch of the multi-symptom cough/cold lozenge Sept. 27. With dyclonine, zinc and vitamin C, Sucrets Complete has the "optimal combination of ingredients to satisfy consumer needs," Nugent said. "This is the biggest news, the biggest idea in this category in 25 years." The launch is "the first stage in a complete brand revitalization program" as the company strives to reinforce its message that Sucrets is a "serious solution" for cough, cold and sore throat symptoms. The firm will promote Sucrets Complete through a multimedia advertising campaign involving print and radio ads, scheduled to launch in the mid-October. Available in two flavors, Vapor Cherry and Cool Citrus, Sucrets Complete will retail for $3.49-$4.99...

You may also be interested in...

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

AstraZeneca Vaccine May Only Gain EU Approval In Under 70s

AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.

Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug

The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts